Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q3 2025 value amounting to $11.0 million.

  • Vanda Pharmaceuticals' Other Non-Current Liabilities rose 1854.87% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 1854.87%. This contributed to the annual value of $9.6 million for FY2024, which is 860.99% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $11.0 million, which was up 1854.87% from $10.0 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $11.0 million for Q3 2025, and its period low was $1.0 million during Q1 2022.
  • Its 5-year average for Other Non-Current Liabilities is $6.6 million, with a median of $6.6 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 6109.23% in 2022, then skyrocketed by 54007.74% in 2023.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $4.4 million in 2021, then soared by 54.9% to $6.8 million in 2022, then rose by 29.81% to $8.8 million in 2023, then rose by 8.61% to $9.6 million in 2024, then rose by 15.2% to $11.0 million in 2025.
  • Its Other Non-Current Liabilities was $11.0 million in Q3 2025, compared to $10.0 million in Q2 2025 and $9.2 million in Q1 2025.